Cadrenal Therapeutics Reports Increased Losses Amid Ongoing Operations and Funding Activities in Q1 2025

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) - Q1 2025 Financial Summary

Cadrenal Therapeutics reported its quarterly financial results for the period ending March 31, 2025, revealing significant developments in its ongoing operations and financial performance.

Positive Aspects:

• Total Revenue: Revenue for the quarter was $82,596, slightly down from $92,327 in Q1 2024.
• Cash Position: The company had cash and cash equivalents of $7,336,072, down from $10,017,942 in the previous quarter but still substantial for ongoing operations.
• Funding Activities: Raised approximately $2 million from sales of common stock through its at-the-market facility, with further sales generating an additional ~$876,000 in May 2025.
• Research Focus: The company is developing tecarfarin for unmet cardiovascular needs, receiving orphan drug designations from the FDA for certain indications.

Negative Aspects:

• Net Loss: The company reported a net loss of $3,845,380 for Q1 2025, compared to $1,663,288 in Q1 2024, showing a substantial increase in losses.
• Operating Expenses: Total operating expenses grew significantly to $3,927,976, up from $1,755,615 in the same quarter last year, attributed mainly to increases in administrative and research-related expenses.
• Accumulated Deficit: The accumulated deficit reached approximately $29.6 million as of March 31, 2025, worsening from $25.7 million at the end of the prior quarter.
• Shares Outstanding: The weighted average number of shares used in computing net loss per common share increased to 1,844,072 from 1,067,231, indicating dilution for existing shareholders.

Key Financial Metrics:

• Total Assets: $7,953,262 as of March 31, 2025.
• Current Liabilities: $1,840,166, a reduction from $2,683,958 in the previous quarter.
• General and Administrative Expenses: $2,254,577 for Q1 2025, representing a 100% increase year-over-year.
• Research and Development Expenses: Increased by 165% to $1,667,882 compared to the prior year.
• Net Loss Per Share: $2.09, up from $1.56 in Q1 2024, reflecting a heavier loss burden per share.

Cadrenal continues navigating a challenging financial landscape, marked by rising expenses and ongoing losses, while striving to advance its innovative therapeutic candidate, tecarfarin, aimed at critical unmet medical needs in anticoagulation therapy.